Back

Two-year outcomes of dabigatran etexilate treatment in patients with co-morbid heart failure and atrial fibrillation: the GLORIA-AF registry

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 3 - Atrial fibrillation - Epidemiology prognosis outcome Heart Failure in Atrial Fibrillation ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Sergio Jose Dubner

Buenos Aires (Argentina)

9 More presentations in this session

Presentation thumbnail
Clinical significance of postoperative atrial arrhythmias in patients who underwent lung transplantation
Doctor B. Kim (Seoul, KR)
Abstract Slides
Presentation thumbnail
The CHA2DS2VASc score as a predictor of cardiovascular events in patients without atrial fibrillation
Assistant Professor F. Ricci (Chieti, IT)
Abstract Slides
Presentation thumbnail
Baseline stroke and bleeding risks in the global edoxaban treatment in routine clinical practice in patients with non-valvular atrial fibrillation programme (global ETNA-AF): first snapshot analysis
Professor P. Kirchhof (Hamburg, DE)
Abstract
Presentation thumbnail
Paroxysmal atrial fibrillation is very common in a geriatric population evaluated for syncope
Doctor R. Jansen (Alkmaar, NL)
Abstract
Presentation thumbnail
The economic burden attributable to atrial fibrillation in nine European countries: perspectives from the GARFIELD-AF registry
Mr P. Cozzolino (Monza, IT)
Abstract

Access the full session

Session thumbnail
Poster Session 3 - Atrial fibrillation - Epidemiology prognosis outcome

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources